Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HCK1
UPID:
ZDBF2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HCK1; Q6ZNP7; Q6ZSN8
Background:
DBF4-type zinc finger-containing protein 2 plays a crucial role in cellular processes, characterized by its unique DBF4-type zinc finger domain. This domain suggests its involvement in DNA replication and cell cycle regulation, highlighting its importance in maintaining cellular integrity and function.
Therapeutic significance:
Understanding the role of DBF4-type zinc finger-containing protein 2 could open doors to potential therapeutic strategies. Its pivotal role in cell cycle regulation makes it a promising target for developing treatments for diseases characterized by uncontrolled cell proliferation.